시장보고서

상품코드

1555712

세계의 주사용 나노의약품 시장 : 제품 유형별, 치료 영역별, 투여 경로별, 최종 사용자별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Injectable Nanomedicines Market, By Product Type, By Therapeutic Area, By Route of Administration, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 08월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 388 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

주사용 나노의약품 시장 규모는 2023년 6억 5,456만 달러로 2024년부터 2032년까지 복합 연간 성장률(CAGR) 8.3%로 확대될 전망입니다.

주사용 나노의약품 시장 : 시장 역학

만성 질환 증가는 주사 나노 의약품의 요구를 촉진할 전망입니다

암, 당뇨병, 심혈관질환, 자가면역질환 등 만성질환의 유병률 증가가 주사용 나노의약품을 포함한 혁신적인 치료방법의 필요성을 높이고 있습니다. 주사 나노 메디신은 병적 조직과 세포에 약물을 특이 적으로 전달하고 건강한 조직에 대한 부작용을 완화하도록 설계 할 수 있습니다. 미국 식품의약국(FDA)은 주사용 나노의약품 시장 형성에 매우 중요한 역할을 합니다. FDA의 엄격한 승인 프로세스는 이러한 혁신적인 치료법의 안전성과 효과를 보장하지만 시장 진입을 목표로하는 기업에게는 도전이기도합니다. 나노메디신은 만성 질환의 관리에 필수적인 통제된 지속적인 약물 방출을 가능하게 합니다. 이것은 장기간에 걸쳐 치료제 수준을 유지하고, 주사 빈도를 줄이고, 환자의 컴플라이언스를 향상시키는 데 도움이 됩니다. 세계보건기구(WHO)에 따르면 인도에서는 고령자의 21%가 적어도 하나의 만성질환을 갖고 있으며, 농촌에서는 17%, 도시에서는 29%입니다. 미국에서는 60세 이상 성인의 95% 가까이가 적어도 하나의 만성 질환을 갖고 있으며, 80% 가까이가 2개 이상의 만성 질환을 가졌습니다.

주사용 나노의약품 시장 : 주요 인사이트력

조사 분석가의 분석에 따르면 시장은 예측 기간 동안에 약 8.3%의 복합 연간 성장률(CAGR)로 매년 성장할 것으로 예측됩니다.

제품 유형별로 폴리머 나노입자가 2023년에 가장 높은 시장 점유율을 보였습니다.

치료 영역의 세분화에 기초하여, 2023년에는 종양가 주요 유형이었습니다.

최종 사용자별로 2023년에는 병원이 주요 유형이었습니다.

지역별로는 북미가 2023년 수익으로 이끌었습니다.

주사용 나노의약품 시장 : 세분화 분석 :

주사용 나노의약품 시장은 제품 유형, 치료 영역, 투여 경로, 최종 사용자 및 지역에 따라 세분화됩니다.

시장은 제품 유형에 따라 5가지로 분류된다: 리포좀, 폴리머 나노입자, 금속 나노입자, 덴드리머, 미셀. 예측 기간 동안 지난 몇 년동안 크게 성장한 폴리머 나노입자에 대한 수요가 더욱 증가할 것으로 예상됩니다. 나노테크놀로지(NP)는 나노의료 비즈니스의 혁명적 발견의 최전선으로 과학적 한계를 넓혀 암, 신경질환, 심혈관질환 등의 분야에 영향을 미치고 있습니다. 아시아태평양 정부의 나노의료에서 R&D(R&D)의 목표는 이 분야의 리더가 되고 특정 사회적 요건을 해결하는 것입니다.

시장은 용도에 따라 네 가지 범주로 나뉩니다. 병원, 클리닉, 연구소 및 기타. 주사 나노 의약품은 특정 세포와 조직에 직접 약물을 전달하도록 설계 될 수 있습니다. 이 정밀도는 부작용을 줄이고 치료 효과를 높입니다. 나노의약품은 개별 환자의 요구에 맞출 수 있으므로 보다 개별화되고 효과적인 치료 계획이 가능합니다. 이것은 암과 같은 복잡한 질병의 치료에 특히 유용합니다.

주사용 나노의약품 시장 : 지리적 인사이트

지리적으로 북미와 유럽은 견고한 연구 인프라와 지원 규제 프레임워크을 통해 주요 지역이되었습니다. 하지만 아시아태평양 신흥 시장은 의료투자 증가와 선진의료기술 채택으로 급성장하고 있습니다. 북미는 강력한 헬스케어 인프라, 광범위한 연구개발 능력, 첨단 의료 기술 채용률의 높이를 배경으로 주사용 나노의약품 시장에서 중요한 위치를 차지하고 있습니다. 미국은 나노테크놀로지 연구를 위한 왕성한 자금과 주요 제약, 바이오테크놀러지 기업의 강력한 존재에 힘입어 이 지역을 선도하고 있습니다. 이 시장은 또한 암, 당뇨병, 심혈관 질환 등의 만성 질환의 유병률이 높아지기도 하며, 나노의약품과 같은 고급 치료 옵션이 필요합니다. 유럽의약청(EMA)은 이 지역에서 나노의약품의 승인과 상업화를 감독하는 주요 규제기관입니다. EMA의 규제는 엄격하다고 생각되는 경향이 있지만, 기업이 나노의약품을 개발, 판매하기 위한 명확한 틀을 제공합니다. Horizon 2020 프로그램과 같은 유럽 연합의 이니셔티브도 나노메디신의 연구와 혁신을 지원하는 데 중요한 역할을 하고 있습니다.

주사용 나노의약품 시장 : 경쟁 구도:

주사용 나노의약품 시장의 주요 기업으로는 Pfizer Inc., AstraZeneca PLC, Sanofi, Johnson & Johnson, Moderna, Inc., Novartis AG etc. 등이 있습니다. 나노의약품 개발과 상업화를 가속화하기 위해 학술기관, 연구기관, 기타 제약기업과의 제휴가 늘고 있습니다. Pfizer Inc.는 파트너십과 인수를 활용하여 리포솜 제제 및 나노입자 기반 치료에 초점을 맞추어 주사용 나노의약품, 포트폴리오를 강화하고 있습니다. Novartis AG etc.는 연구개발에 많은 투자를 하고 학술기관과 협력하여 특히 표적 약물전달에서 차세대 나노메디신을 개발하기 위해 노력하고 있습니다. Bristol-Myers Squibb Company는 특히 암 영역에서 생물 제제의 전달을 강화하기 위해 나노기술을 중시하고 있으며, 나노메디신 후보의 강력한 파이프라인을 가지고 있습니다. AstraZeneca PLC는 특히 암 영역에서 표적 약물 전달을 위해 나노기술을 이용하고 있으며, 나노메디신의 능력을 확대하기 위해 제휴 및 공동 연구에 투자하고 있습니다.

소개
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 - 주사용 나노의약품 업계

경쟁 대시보드
기업 프로파일
- Pfizer Inc.
- AstraZeneca PLC
- Johnson &Johnson
- Sanofi
- Merck &Co., Inc.
- Moderna, Inc.
- Amgen Inc.
- Novartis AG
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- Bristol-Myers Squibb
- Teva Pharmaceutical Industries Ltd.
- Nanobiotix SA
- CytImmune Sciences, Inc.
- BIND Therapeutics, Inc.
- Others

제13장 애널리스트의 전방위 전망

BJH 24.10.11

REPORT HIGHLIGHT

Injectable Nanomedicines Market size was valued at USD 654.56 million in 2023, expanding at a CAGR of 8.3% from 2024 to 2032.

The Injectable Nanomedicines market involves the development, production, and commercialization of nanoscale drugs that are administered via injection. These nanomedicines leverage the unique properties of nanoparticles to enhance drug delivery, targeting, and efficacy, particularly in treating diseases such as cancer, cardiovascular disorders, and infectious diseases. Key drivers of the market include advancements in nanotechnology, increased prevalence of chronic diseases, and the demand for targeted therapies that reduce side effects. Additionally, government support for nanomedicine research and development, along with growing investments from pharmaceutical companies, is propelling market growth. Challenges in the market include high production costs, regulatory complexities, and potential safety concerns related to the long-term effects of nanoparticles on the human body. Despite these hurdles, the market is expected to grow significantly due to the increasing number of nanomedicine products in the pipeline and their promising therapeutic outcomes.

Injectable Nanomedicines Market- Market Dynamics

The increasing prevalence of chronic diseases driving the need for injectable nanomedicines

The increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular diseases, and autoimmune disorders is driving the need for innovative treatment approaches, including injectable nanomedicines. Injectable nanomedicines can be designed to deliver drugs specifically to diseased tissues or cells, reducing the side effects on healthy tissues. The U.S. Food and Drug Administration (FDA) plays a pivotal role in shaping the injectable nanomedicine market. The FDA's stringent approval process ensures the safety and efficacy of these innovative therapies, but it also poses a challenge for companies seeking market entry. Nanomedicines can provide controlled and sustained drug release, which is critical for managing chronic diseases. This helps in maintaining therapeutic drug levels over an extended period, reducing the frequency of injections and improving patient compliance. According to the World Health Organization (WHO), In India, 21% of the elderly have at least one chronic disease, with 17% in rural areas and 29% in urban areas. In the US, nearly 95% of adults 60 and older have at least one chronic condition, and nearly 80% have two or more.

Injectable Nanomedicines Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.3% over the forecast period (2024-2032)

Based on product type segmentation, Polymeric Nanoparticles were predicted to show maximum market share in the year 2023

Based on Therapeutic Area segmentation, Oncology was the leading type in 2023

Based on End User segmentation, Hospitals were the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Injectable Nanomedicines Market- Segmentation Analysis:

The Global Injectable Nanomedicines Market is segmented based on Product Type, Therapeutic Area, Route of Administration, End User, and Region.

The market is divided into five categories based on product type: Liposomes, Polymeric Nanoparticles, Metal Nanoparticles, Dendrimers, and Micelles. Throughout the projection period, there is expected to be a further increase in demand for polymeric nanoparticles, which has grown significantly in the last few years. Nanotechnology (NP) is influencing disciplines such as cancer, neurological disorders, and cardiovascular diseases by pushing scientific limits to the forefront of revolutionary discoveries for the nanomedicine business. The goal of the Asia Pacific government's research and development (R&D) in nanomedicine is to be a leader in the field and to solve certain social requirements.

The market is divided into four categories based on application: Hospitals, Clinics, Research Laboratories, and Others. Injectable nanomedicines can be engineered to deliver drugs directly to specific cells or tissues, such as targeting cancer cells while sparing healthy ones. This precision reduces side effects and increases treatment efficacy. Nanomedicines can be tailored to the individual patient's needs, allowing for more personalized and effective treatment plans. This can be particularly beneficial in treating complex diseases like cancer.

Injectable Nanomedicines Market- Geographical Insights

Geographically, North America and Europe are leading regions due to robust research infrastructure and supportive regulatory frameworks. However, emerging markets in Asia-Pacific are witnessing rapid growth due to increasing healthcare investments and the adoption of advanced medical technologies. North America is a significant player in the injectable nanomedicines market, driven by its strong healthcare infrastructure, extensive R&D capabilities, and high adoption of advanced medical technologies. The United States leads the region, supported by robust funding for nanotechnology research and a strong presence of key pharmaceutical and biotech companies. The market is also bolstered by a high prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions, which necessitate advanced therapeutic options like nanomedicines. The European Medicines Agency (EMA) is the primary regulatory body overseeing the approval and commercialization of nanomedicines in the region. The EMA's regulations are often seen as rigorous, but they provide a clear framework for companies to develop and market nanomedicines. The European Union's initiatives, such as the Horizon 2020 program, have also played a crucial role in supporting nanomedicine research and innovation.

Injectable Nanomedicines Market- Competitive Landscape:

Major players in the Injectable Nanomedicines Market include Pfizer Inc., AstraZeneca PLC, Sanofi, Johnson & Johnson, Moderna, Inc., Novartis AG etc. Companies are increasingly collaborating with academic institutions, research organizations, and other pharmaceutical companies to accelerate the development and commercialization of nanomedicines. Pfizer leverages partnerships and acquisitions to enhance its injectable nanomedicine portfolio, focusing on liposomal formulations and nanoparticle-based therapies. Novartis invests heavily in R&D and collaborates with academic institutions to develop next-generation nanomedicines, particularly in targeted drug delivery. Bristol-Myers Squibb Company emphasizes nanotechnology to enhance the delivery of its biologics, particularly in oncology, with a strong pipeline of nanomedicine candidates. AstraZeneca uses nanotechnology for targeted drug delivery, particularly in oncology, and invests in partnerships and collaborations to expand its nanomedicine capabilities.

Recent Developments:

In March 2021, PACIRA Biosciences, Inc. Got FDA Approval For Exparel (Bupivacaine Liposome Injectable Suspension) Which Is A New Drug Application In Pediatric Patients.

In March 2021, Jazz Pharmaceutical Announced Additional Vyxeos (Daunorubicin And Cytarabine) For The Treatment Of Secondary Acute Myeloid Leukemia.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INJECTABLE NANOMEDICINES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Pfizer Inc.
AstraZeneca PLC
Johnson & Johnson
Sanofi
Merck & Co., Inc.
Moderna, Inc.
Amgen Inc.
Novartis AG
F. Hoffmann-La Roche AG
Gilead Sciences, Inc.
Bristol-Myers Squibb
Teva Pharmaceutical Industries Ltd.
Nanobiotix SA
CytImmune Sciences, Inc.
BIND Therapeutics, Inc.
Others

GLOBAL INJECTABLE NANOMEDICINES MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

Liposomes
Polymeric Nanoparticles
Metal Nanoparticles
Dendrimers
Micelles

GLOBAL INJECTABLE NANOMEDICINES MARKET, BY THERAPEUTIC AREA - MARKET ANALYSIS, 2019 - 2032

Oncology
Cardiovascular Diseases
Neurological Disorders
Infectious Diseases
Autoimmune Diseases

GLOBAL INJECTABLE NANOMEDICINES MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Intravenous (IV) Injection
Subcutaneous Injection
Intramuscular Injection
Intrathecal Injection

GLOBAL INJECTABLE NANOMEDICINES MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Clinics
Research Laboratories
Others

GLOBAL INJECTABLE NANOMEDICINES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Injectable Nanomedicines Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Injectable Nanomedicines Market Snippet by Product Type
- 2.1.2. Injectable Nanomedicines Market Snippet by Therapeutic Area
- 2.1.3. Injectable Nanomedicines Market Snippet by Route of Administration
- 2.1.4. Injectable Nanomedicines Market Snippet by End User
- 2.1.5. Injectable Nanomedicines Market Snippet by Country
- 2.1.6. Injectable Nanomedicines Market Snippet by Region
2.2. Competitive Insights

3. Injectable Nanomedicines Key Market Trends

3.1. Injectable Nanomedicines Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Injectable Nanomedicines Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Injectable Nanomedicines Market Opportunities
3.4. Injectable Nanomedicines Market Future Trends

4. Injectable Nanomedicines Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Injectable Nanomedicines Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Injectable Nanomedicines Market Landscape

6.1. Injectable Nanomedicines Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Injectable Nanomedicines Market - By Product Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Product Type, 2023 & 2032 (%)
- 7.1.2. Liposomes
- 7.1.3. Polymeric Nanoparticles
- 7.1.4. Metal Nanoparticles
- 7.1.5. Dendrimers
- 7.1.6. Micelles

8. Injectable Nanomedicines Market - By Therapeutic Area

8.1. Overview
- 8.1.1. Segment Share Analysis, By Therapeutic Area, 2023 & 2032 (%)
- 8.1.2. Oncology
- 8.1.3. Cardiovascular Diseases
- 8.1.4. Neurological Disorders
- 8.1.5. Infectious Diseases
- 8.1.6. Autoimmune Diseases

9. Injectable Nanomedicines Market - By Route of Administration

9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 9.1.2. Intravenous (IV) Injection
- 9.1.3. Subcutaneous Injection
- 9.1.4. Intramuscular Injection
- 9.1.5. Intrathecal Injection

10. Injectable Nanomedicines Market - By End User

10.1. Overview
- 10.1.1. Segment Share Analysis, By Therapeutic Area, 2023 & 2032 (%)
- 10.1.2. Hospitals
- 10.1.3. Clinics
- 10.1.4. Research Laboratories
- 10.1.5. Others

11. Injectable Nanomedicines Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Injectable Nanomedicines Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Injectable Nanomedicines Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.9. Italy
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.9.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.10. United Kingdom
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. United Kingdom Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4. United Kingdom Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.11. France
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.11.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.12. Russia
  - 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.2. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.12.3. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.13. Netherlands
  - 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.2. Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.13.3. Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.2. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.15. Poland
  - 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.2. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.15.3. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.3.16. Rest of Europe
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Injectable Nanomedicines Key Manufacturers in Asia Pacific
- 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.4.5. Asia Pacific Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.8. India
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.8.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.9. China
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.9.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.13. Thailand
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.14. Indonesia
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5. Latin America
- 11.5.1. Overview
- 11.5.2. Injectable Nanomedicines Key Manufacturers in Latin America
- 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. Latin America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.5.5. Latin America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Injectable Nanomedicines Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Injectable Nanomedicines Industry

12.1. Competitive Dashboard
12.2. Company Profiles
- 12.2.1. Pfizer Inc.
- 12.2.2. AstraZeneca PLC
- 12.2.3. Johnson & Johnson
- 12.2.4. Sanofi
- 12.2.5. Merck & Co., Inc.
- 12.2.6. Moderna, Inc.
- 12.2.7. Amgen Inc.
- 12.2.8. Novartis AG
- 12.2.9. F. Hoffmann-La Roche AG
- 12.2.10. Gilead Sciences, Inc.
- 12.2.11. Bristol-Myers Squibb
- 12.2.12. Teva Pharmaceutical Industries Ltd.
- 12.2.13. Nanobiotix SA
- 12.2.14. CytImmune Sciences, Inc.
- 12.2.15. BIND Therapeutics, Inc.
- 12.2.16. Others

13. 360 Degree Analyst View

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us